Second-line endocrine therapy (ET) with or without palbociclib (P) maintenance in patients (pts) with hormone receptor-positive (HR[+])/human epidermal growth factor receptor 2-negative (HER2[-]) advanced breast cancer (ABC): PALMIRA trial.

Bibliographic Details
Title:	Second-line endocrine therapy (ET) with or without palbociclib (P) maintenance in patients (pts) with hormone receptor-positive (HR[+])/human epidermal growth factor receptor 2-negative (HER2[-]) advanced breast cancer (ABC): PALMIRA trial.
Authors:	Llombart-Cussac, Antonio, Harper-Wynne, Catherine, Perello, Antonia, Hennequin, Audrey, Fernandez, Adela, Colleoni, Marco, Carañana, Vicente, Quiroga, Vanesa, Medioni, Jacques, Iranzo, Vega, Wheatley, Duncan, Del Barco, Sonia, Anton, Antonio, Dobi, Erion, Ruiz-Borrego, Manuel, Alcalá-López, Daniel, Pérez-Escuredo, Jhudit, Sampayo-Cordero, Miguel, Pérez-García, José Manuel, Cortes, Javier
Source:	Journal of Clinical Oncology; 2023 Supplement 16, Vol. 41, p1001-1001, 1p
Database:	Supplemental Index

More Details
ISSN:	0732183X
DOI:	10.1200/JCO.2023.41.16_suppl.1001
Published in:	Journal of Clinical Oncology
Language:	English